Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Items 201–267 of 267
Inhibition of G-protein-coupled Receptor Function by Disruption of Transmembrane Domain Interactions
Tarasova, N. I., Rice, W. G., & Michejda, C. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34911 · Cited by 88 · cited 1×
“Peptide analogues of TMDs are believed to interfere with the proper assembly or function of the target protein, as was shown in experiments aimed at the in vitro”
BackgroundABCG2 (BCRP) expression in normal and malignant hematopoietic cells
Abbott, B. L. (2003) · Hematological Oncology · doi:10.1002/hon.714 · Cited by 87 · cited 1×
“Transported substrates include cytotoxic drugs, toxins and carcinogens found in food products, as well as endogenous compound”
BackgroundActive Efflux of CPT-11 and Its Metabolites in Human KB-Derived Cell Lines
Chu, X.-Y., Suzuki, H., Ueda, K., Kato, Y., Akiyama, S.-I., & Sugiyama, Y. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38014-0 · Cited by 86
Jorajuria, S., Dereuddre‐Bosquet, N., Bécher, F., Martin, S., Porcheray, F., Garrigues, A., Mabondzo, A. M., Bénech, H., Grassi, J. J., Orlowski, S., et al. (2004) · Antiviral Therapy · doi:10.1177/135965350400900403 · Cited by 85
Dietrich, C. G. (2001) · Carcinogenesis · doi:10.1093/carcin/22.5.805 · Cited by 85 · cited 1×
“So, MRP2 has a pivotal role in the export of organic anions, unconjugated bile acids and xenobiotics into the bile, and also contributes to protection against orally ingested drug”
BackgroundLaing, N. M., Belinsky, M. G., Kruh, G. D., Bell, D. W., Boyd, J. T., Barone, L. R., Testa, J. R., & Tew, K. D. (1998) · PubMed · Cited by 83
Development of Multidrug-Resistance Convertors: Sense or Nonsense?
van Zuylen, L., Nooter, K., Sparreboom, A., & Verweij, J. (2000) · Investigational New Drugs · doi:10.1023/a:1006487003814 · Cited by 83
Perego, P., Cesare, M. D., Isabella, P. D., Carenini, N., Beggiolin, G., Pezzoni, G., Palumbo, M., Tartaglia, L., Pratesi, G., Pisano, C., et al. (2001) · PubMed · Cited by 83
Karászi, É., Jakab, K. T., Homolya, L., Szakács, G., Holló, Z., Telek, B., Kiss, A., Rejtő, L., Nahajevszky, S., Sarkadi, B., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02554.x · Cited by 80 · cited 1×
“Functional assays, such as those using flow cytometry to measure efflux of fluorescent Pgp substrates (for example, Calcein-AM and rhodamine 123) from leukaemic cells, often complement expression analysi”
MethodSelf-citationHaimeur, A., Conseil, G., Deeley, R., & Cole, S. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1375 · Cited by 80
Han, B., & Zhang, J. (2004) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011043482205 · Cited by 79
A High-Throughput Screening Microplate Test for the Interaction of Drugs with P-Glycoprotein
Garrigues, A., Nugier, J., Orlowski, S., & Ezan, É. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5650 · Cited by 75
Inhibitors of Multidrug Efflux Transporters: Their Membrane and Protein Interactions
Seelig, A., & Gatlik-Landwojtowicz, E. (2005) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557053402693 · Cited by 73
Wattel, Solary, É., Hecquet, B., Caillot, Ifrah, N., Brion, Mahé, Milpied, N. J., Janvier, Guerci, et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00870.x · Cited by 72
on behalf of the West of Scotland Lung Cancer Research Group, A. T. A. O. G., & Milroy, R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.433 · Cited by 68
Circumvention of P-GP MDR as a Function of Anthracycline Lipophilicity and Charge
Lampidis, T. J., Kolonias, D. S., Podona, T., Israel, M., Safa, A. R., Lothstein, L., Savaraj, N., Tapiero, H., & Priebe, W. (1997) · Biochemistry · doi:10.1021/bi9614489 · Cited by 68
Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation
Boonstra, R., Timmer‐Bosscha, H., van Echten‐Arends, J., van der Kolk, D. M., van den Berg, A., de Jong, B. M., Tew, K. D., Poppema, S., & de Vries, E. G. E. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601863 · Cited by 68
Klappe, K., Hinrichs, J. W. J., Kroesen, B., Sietsma, H., & Kok, J. W. (2004) · International Journal of Cancer · doi:10.1002/ijc.20140 · Cited by 67
ATP binding cassette transporter gene expression in rat liver progenitor cells
Ros, J. E., Roskams, T., Geuken, M., Havinga, R., Splinter, P. L., Petersen, B. E., LaRusso, N. F., van der Kolk, D. M., Kuipers, F., Faber, K. N., et al. (2003) · Gut · doi:10.1136/gut.52.7.1060 · Cited by 65
Potschka, H., Fedrowitz, M., & Löscher, W. (2003) · Epilepsia · doi:10.1111/j.0013-9580.2003.22603.x · Cited by 63
Strategies for Inhibition of MDR1 Gene Expression
Xu, D., Kang, H. M., Fisher, M. H., & Juliano, R. L. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.2.268 · Cited by 62 · cited 1×
“Sufficient downregulation of Pgp has proved difficult to attain and the safe delivery of constructs to cancer cells in vivo remains a challeng”
BackgroundRelling, M. V. (1996) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199608000-00006 · Cited by 60
Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides
Kang, H. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh775 · Cited by 58
How Cancer Could be Cured by 2015
Blagosklonny, M. V. (2004) · Cell Cycle · doi:10.4161/cc.4.2.1493 · Cited by 55
Norman, B. H., Lander, P. A., Gruber, J. M., Kroin, J. S., Cohen, J. D., Jungheim, L. N., Starling, J. J., Law, K. L., Self, T. D., Tabas, L. B., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.08.075 · Cited by 53
Transmembrane Inhibitors of P-Glycoprotein, an ABC Transporter
Tarasova, N. I., Seth, R., Tarasov, S. G., Kosakowska‐Cholody, T., Hrycyna, C. A., Gottesman, M. M., & Michejda, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049065t · Cited by 52 · cited 1×
“Small peptides designed to correspond to the transmembrane segments of Pgp act as specific and potent inhibitors, suggesting that TMDs of ABC transporters can also serve as templates for inhibitor desig”
BackgroundSelf-citationPatterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line
Cole, S. P. C. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf02897225 · Cited by 51
Diagnostics of multidrug resistance in cancer
Gergely, S., Katalin, J., Antal, F., & Balázs, S. (1998) · Pathology & Oncology Research · doi:10.1007/bf02905214 · Cited by 51 · cited 1×
“Functional assays, such as those using flow cytometry to measure efflux of fluorescent Pgp substrates (for example, Calcein-AM and rhodamine 123) from leukaemic cells, often complement expression analysi”
MethodYamada, A., Kawano, K., Koga, M., Matsumoto, T., & Itoh, K. (2001) · PubMed · Cited by 50
Tribull, T. E., Bruner, R. H., & Bain, L. J. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(02)00485-x · Cited by 50
Turzanski, J., Grundy, M. A., Shang, S., Russell, N. H., & Pallis, M. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.10.005 · Cited by 50
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
Ross, D. D. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.014 · Cited by 50
Hofmann, J., Wolf, A., Spitaler, M., B�ck, G., Drach, J. W., Ludescher, C., & Grunicke, H. H. (1992) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01294440 · Cited by 49
Kaplan, O., Jaroszewski, J. W., Clarke, R. C., Fairchild, C. R., Schoenlein, P. V., Goldenberg, S., Gottesman, M. M., & Cohen, J. S. (1991) · PubMed · Cited by 49
Self-citationBell, S., Quinn, D., Kellett, G., & Warr, Jr. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.708 · Cited by 48
Michieli, M., Damiani, D., Ermacora, A., Geromin, A., Michelutti, A., Masolini, P., & Baccarani, M. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01957.x · Cited by 48 · cited 1×
“, and its prognostic implication in chronic lymphocytic and promyelocytic leukaemia, non-small-cell lung cancer (NSCLC) and breast cancer remains controversia”
BackgroundXu, D., Ye, D., Fisher, M., & Juliano, R. L. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033639 · Cited by 47
Dantzig, A. H., Shepard, R. L., Pratt, S. E., Tabas, L. B., Lander, P. A., Ma, L., Paul, D. C., Williams, D. C., Peng, S.-B., Slapak, C. A., et al. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.11.006 · Cited by 43
Daenen, S. M. G. J., van der Holt, B., Verhoef, G. E. G., Löwenberg, B., Wijermans, P., Huijgens, P. C., Kooy, R. V. M., Schouten, H. C., Kramer, M. H. H., Ferrant, A., et al. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.03.001 · Cited by 40 · cited 1×
“However, several other trials failed to show improvement of the outcome and toxic side effects were commo”
BackgroundInhibitors of P-Glycoprotein - Lead Identification and Optimisation
Pleban, K., & Ecker, G. F. (2005) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557053402729 · Cited by 40
The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation
Bentley, J. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)04739-3 · Cited by 38
Lehne, G., Angelis, P. D., den Boer, M. L., & Rugstad, H. (1999) · Leukemia · doi:10.1038/sj.leu.2401392 · Cited by 37
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
ROSS, D. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/s1521-6926(04)00080-5 · Cited by 37
Byrne, J., Das-Gupta, E. P., Pallis, M., Turzanski, J., Forman, K., Mitchell, D., Haynes, A. P., & Russell, N. H. (1999) · Leukemia · doi:10.1038/sj.leu.2401406 · Cited by 34
The reversal of multidrug resistance: an update
Kellen, J. A. (2003) · Journal of Experimental Therapeutics and Oncology · doi:10.1046/j.1359-4117.2003.01067.x · Cited by 34 · cited 1×
“Indeed, due to the promiscuity of the transporter, it has been relatively easy to find non-toxic, high-affinity substrates that block transport in a competitive or non-competitive manne”
BackgroundWattel, E., Solary, É., Hecquet, B., Caillot, D., Ifrah, N., Brion, A., Milpied, N. J., Janvier, M., Guerci‐Bresler, A., Rochant, H., et al. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4811-9_5 · Cited by 33
Wood, L., Palmer, M., Hewitt, J., Urtasun, R. C., Bruera, E. D., Rapp, E., & Thaell, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.100 · Cited by 33
Guns, E. S. T., Denyssevych, T., Dixon, R., Bally, M. B., & Mayer, L. D. (2002) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190426 · Cited by 32
Heike, Y., Hamada, H., Inamura, N., Sone, S., Ogura, T., & Tsuruo, T. (1990) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1990.tb02528.x · Cited by 31 · cited 1×
“Anti-Pgp antibodies have been successfully used to destroy Pgp-expressing cells in antibody-mediated cytolysis experiments, and have also been used as immunotoxin”
MethodMarie, J., Legrand, O., Perrot, J., Chevillard, S., Huet, S., & Robert, J. (1997) · PubMed · Cited by 30
George, S. R., Ng, G., Lee, S. P., Fan, T., Varghese, G. K., Wang, C., Deber, C. M., Seeman, P. M., & O’Dowd, B. F. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053843 · Cited by 29
Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins
Beck, W., & Grogan, T. (1997) · Leukemia · doi:10.1038/sj.leu.2400675 · Cited by 29
P-glycoprotein mediates profound resistance to bisantrene.
Zhang, X. P., Ritke, M. K., Yalowich, J. C., Slovak, M. L., Ho, J. P., Collins, K. I., Annable, T., Arceci, R. J., Durr, F. E., & Greenberger, L. M. (1994) · PubMed · Cited by 29
Maslak, P. G., Weiss, M., Berman, E., Yao, T. J., Tyson, D., Golde, D. W., & Scheinberg, D. A. (1996) · PubMed · Cited by 29
Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia
Pallis, M., & Russell, N. H. (2004) · Leukemia · doi:10.1038/sj.leu.2403511 · Cited by 27
Consoli, U., Van, N., Neamati, N., Mahadevia, R., Beran, M., Zhao, S., & Andreeff, M. (1997) · Leukemia · doi:10.1038/sj.leu.2400511 · Cited by 27
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
Fracasso, P. M., Blum, K. A., Ma, M. K., Tan, B. R., Wright, L. P., Goodner, S. A., Fears, C. L., Hou, W., Arquette, M. A., Picus, J., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602653 · Cited by 27
Lehne, G., Sørensen, D., Tjonnfjord, G., Beiske, C., Hagve, T.-A., Rugstad, H., & Clausen, O. P. F. (2002) · Leukemia · doi:10.1038/sj.leu.2402663 · Cited by 25
Licht, T., Goldenberg, S., Vieira, W. D., Gottesman, M. M., & Pastan, I. H. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301087 · Cited by 25
Self-citationMDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype.
Hegewisch-Becker, S. (1996) · PubMed · Cited by 23
Flow Cytometric Measurement of Functional and Phenotypic P-Glycoprotein
Pallis, M., & Das-Gupta, E. P. (2005) · Humana Press eBooks · doi:10.1385/1-59259-889-7:167 · Cited by 20
Inhibition of multidrug resistance by immunisation with synthetic P-glycoprotein-derived peptides
Pawlak-Roblin, C., Tosi, P. F., Perrin, L., Devy, J., Ventéo, L., Albert, P., Nicolau, C. S., & Madoulet, C. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.019 · Cited by 18
The preferential induction of apoptosis in multidrug-resistant KB cells by 5-fluorouracil
Warr, J. R., Bamford, A. I., & Quinn, D. M. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00721-2 · Cited by 18
Wattel, E., Solary, É., Hecquet, B., Caillot, D., Ifrah, N., Brion, A., Milpied, N. J., Janvier, M., Guerci‐Bresler, A., Rochant, H., et al. (1999) · Cited by 15
Robert, J. (2004) · PubMed · Cited by 13
Warr, J. R., Quinn, D., Elend, M., & Fenton, J. A. L. (1995) · Cancer Letters · doi:10.1016/s0304-3835(06)80019-4 · Cited by 8 · cited 1×
“MDR cells were found to be collaterally sensitive to membrane-active agents such as the calcium-channel blocker verapamil; inhibitors such as PSC-833 or LY294002 (Ref”
BackgroundAlmost Serendipity: Alcoholism Drug Reverses Drug Resistance In Vitro
Vastag, B. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.864 · Cited by 3
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
“, glutathione S-transferase) or resistance to apoptosis/senescence pathways [239-242].”
BackgroundKamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
ROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.